Lexagene Holdings Inc is Shariah compliant. The company’s financials pass three standards and fail in two.
Ad
LXG – Lexagene Holdings Inc
Compliant
★★★☆☆
- Biotechnology & Medical Research
- Toronto Venture Exchange
- July 16, 2022
$20,516,091
Market cap
0%
Revenue Growth
BUY
Analysts' Rating
AAOIFI
S&P
DJIM
FTSE
MSCI
AAOIFI
AAOIFI ✓
| Debt ÷ Market cap (MC) | 7.77% | ✓ |
| Non-Compliant Assets ÷ MC | % |
S&P
S&P ✓
| Debt ÷ 36 mo MC | 3.13% | ✓ |
| Cash ÷ 36 mo MC | 18.9% | ✓ |
| AR ÷ 36 mo MC | % |
DJIM
DJIM ✓
| Debt ÷ 24 mo MC | 2.82% | ✓ |
| Cash ÷ 24 mo MC | 17.03% | ✓ |
| AR ÷ 24 mo MC | % |
FTSE
FTSE ✗
| Debt ÷ Assets | 12.09% | ✓ |
| Cash ÷ Assets | 72.94% | ✗ |
| Cash&AR ÷ Assets | 72.94% | ✗ |
MSCI
MSCI ✗
| Debt ÷ Assets | 12.09% | ✓ |
| Cash ÷ Assets | 72.94% | ✗ |
| Cash&AR ÷ Assets | 72.94% | ✗ |
Ad
Recommendation Rating
2
1
2
3
4
5
1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL
Analysts’ Price Targets
Mean 0.59
Low: 0.59
High: 0.59
Total Analysts: 0
Company Profile
Lexagene Holdings Inc. is a molecular diagnostics company. The Company is focused on developing a fully automated, rapid pathogen detection system for use at the point-of-need where samples are collected, which offers unprecedented ease-of-use, sensitivity, and breadth of pathogen detection. The Company’s MiQLab is an automated, open-access molecular diagnostic system for pathogen detection, allowing users to test for multiple pathogens onsite, returning results in approximately 2 hours. Its on-site, automated rapid pathogen detection technology is used for testing in human clinical diagnostics, veterinary diagnostics, food safety, and more. Its veterinary diagnostics system enables veterinarians to rapidly identify infectious pathogens and antibiotic resistance factors in cats and dogs, providing actionable insights in initial diagnosis and prescribed therapies.
We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan.
Ad
Responses